Aug 2026· IBRO Neuroscience Reports· Vol 21, pp. 518 - 541· 1 citation· 87 references
Medicine
TL;DR
This review synthesizes the context-dependent roles of NF-κB in AD and provides a framework for reconciling its apparently opposing effects, and argues against indiscriminate activation or global inhibition of NF-κB, either of which could disrupt physiological functions while failing to selectively suppress disease-driving pathways.
Abstract
Nuclear factor kappa B (NF-κB) has been implicated in both protective and detrimental processes in Alzheimer disease (AD), creating an apparent contradiction in the literature. Increasing evidence, however, indicates that these divergent effects reflect differences in cell type, molecular configuration, activation kinetics, disease state, and the surrounding pathological environment rather than a true biological paradox. Under transient and tightly regulated conditions, NF-κB can support neuronal survival, stress adaptation, antioxidant defense, and selected compensatory responses to amyloid-β pathology. In contrast, persistent or disease-conditioned signaling is more consistently associated with amyloidogenic processing, tau propagation, chronic neuroinflammation, impaired proteostasis, neuronal dysfunction, and neurovascular injury. The available evidence therefore supports an asymmetric framework in which protective effects are confined to relatively specific molecular and temporal settings, whereas sustained pathological signaling is supported across a broader range of disease-relevant models and cellular processes. This distinction argues against indiscriminate activation or global inhibition of NF-κB, either of which could disrupt physiological functions while failing to selectively suppress disease-driving pathways. Therapeutic strategies should instead target defined pathological NF-κB programs within the relevant cell type and disease context while preserving adaptive and homeostatic signaling. This review synthesizes the context-dependent roles of NF-κB in AD and provides a framework for reconciling its apparently opposing effects.
Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are characterized by progressive neuronal dysfunction and loss driven by convergent pathological mechanisms such as oxidative stress, mitochondrial impairment, protein misfolding, apo...
Priyanka Banerjee, Rakesh Das, Amartya Sen et al.· Discover Neuroscience· 0 citations
This review examines the molecular and cellular mechanisms through which neuroinflammation contributes to the progression of AD, with particular emphasis on microglial activation, TREM2 and soluble TREM2 (sTREM2) signaling, NLRP3 inflammasome activation, astrocyte–microglia interactions, and blood–brain barrier dysfunc...
Shreyansh Goswami· International Journal For Mu...· 0 citations
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
Alzheimer's disease (AD) is characterized by progressive cognitive decline driven by the convergence of tauopathy, impaired proteostasis, and chronic neuroinflammation. Emerging evidence identifies the immunoproteasome (iP), particularly the β5i/LMP7 subunit, as a central regulator linking these pathological processes....
Mustafa M. Shokr, Ahmed M. Abdelaziz· InflammoPharmacology· 0 citations
Multiple factors associated with the AD are discussed, such as Aβ, oxidative stress, and inflammatory signaling, contributing to the phosphorylation, ubiquitination, internalization, and degradation of P-gp, which results in impaired transporter function and a compromised integrity of the BBB.
A. Joshi, Jotiram Salunkhe, Dr. Vinod Ugale· Molecular Biology Reports· 0 citations
The phenotypic and functional alterations of B cells in AD are reviewed, integrating evidence from experimental models and human studies to evaluate whether B cells constitute an underappreciated component of the adaptive immune response in AD and whether they represent a compelling immunotherapeutic target.
Eva-Loren Charavner, S. Fillatreau, M. El Behi· Cellular Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.